

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICES
NATIONAL INSTITUTES OF HEALTH

RECOMBINANT DNA ADVISORY COMMITTEE
POINTS TO CONSIDER SUBCOMMITTEE

1367

MINUTES OF MEETING¹

MARCH 31, 1989

The Points to Consider Subcommittee, Recombinant DNA Advisory Committee, was convened at 9:00 a.m. on March 31, 1989, at the National Institutes of Health, Building 31, Conference Room 10, 9000 Rockville Pike, Bethesda, Maryland 20892. Dr. James Childress was Chair. In accordance with Public Law 92-463, the meeting was open to the public. The following were present for all or part of the meeting.

Subcommittee members:

Judith Areen
James Childress
Maurice Mahoney
Alexander Capron
Robert Murray
Robertson Parkman
Robert Rich
Rachel Levinson
(Executive Secretary)

The subcommittee roster is attached (Attachment I).

Other National Institutes of Health staff:

W. French Anderson, NHLBI
Charles MacKay, OD
Jay Moskowitz, OD
Kristin Olsen, OD


Others:

Bheen Bhat, Wyeth Laboratories
Robert Cook-Deegan, Biomedical Ethics Advisory Committee

¹The subcommittee is advisory to the Recombinant DNA Advisory Committee, and its recommendations should not be considered as final or accepted.

The Points to Consider Subcommittee met on March 31, 1989, and developed a first revision of a document entitled, "Points to Consider in the Design and Submission of Protocols for Human Gene Transfer." This document was originally adopted by the RAC in 1986 with the understanding that it would require periodic updates and revisions as the technology for gene therapy matured and became a reality in practice. The revised document will be forwarded to the July 31, 1989, Human Gene Therapy Subcommittee meeting. The Human Gene Therapy will then forward their recommendations to the Recombinant DNA Advisory Committee for consideration at the October 6, 1989, meeting.

The results of their deliberations of the Points to Consider Subcommittee meeting on March 31, 1989, on the document entitled, "Points to Consider in the Design and Submission of Protocols for Human Gene Transfer" is attached (Attachment II).



Rachel E. Levinson
Executive Secretary

I hereby certify that, to the best of my knowledge, the foregoing minutes are accurate and complete.

James F. Childress, Ph.D.
Chair

Date

RECOMBINANT DNA ADVISORY COMMITTEE

POINTS TO CONSIDER SUBCOMMITTEE

CHAIRMAN

CHILDRESS, James F., Ph.D
Department of Religious Studies
University of Virginia, Cocks Hall
Charlottesville, Virginia 22903
804 924-3741

AREEN, Judith, J.D.
Georgetown University Law Center
600 New Jersey Avenue, N.W.
Washington, DC 20001
202 662-9117

MURRAY, Robert F., M.D.
Division of Medical Genetics
Howard University, Box 75
520 W Street, N.W.
Washington, DC 20059
202 636-6382

MAHONEY, Maurice J., M.D.
Department of Human Genetics
Yale University
333 Cedar Street, 305 WW
New Haven, Connecticut 06510
203 785-2661

PARKMAN, Robertson, M.D.
Division of Research Immunology--
Bone Marrow Transplantation
Childrens Hospital of Los Angeles
Los Angeles, California 90027
213 669-2546

CAPRON, Alexander, LL.B.
The Law Center
University of Southern California
Los Angeles, California 90089-0071
213 743-7734

RICH, Robert F., Ph.D.
Institute of Government & Public
Affairs
University of Illinois
1201 West Nevada
Urbana, Illinois 61801
217 333-3340

EXECUTIVE SECRETARY

LEVINSON, Rachel E.
Office of Recombinant DNA Activities
National Institutes of Health, 31/B1C34
Bethesda, Maryland 20892
301 496-9838

MARCH 1989

151

AD HOC CONSULTANT

EPSTEIN, Charles J., M.D.
Department of Pediatrics, M-650
University of California
San Francisco, California 94143
415 476-2981

NEIMAN, Paul E., M.D.
Associate Director for Basic
Sciences
Fred Hutchinson Cancer Research
Center
1124 Columbia Street
Seattle, Washington 98104
206 467-4417

June 21, 1989

NATIONAL INSTITUTES OF HEALTH
Points to Consider in the Design and Submission of
~~Human Somatic Cell Gene Therapy Protocols~~
Protocols for the Transfer of
Recombinant DNA into Human Subjects

Human Gene Therapy Subcommittee
NIH Recombinant DNA Advisory Committee

OUTLINE

Applicability

Introduction

I. Description of Proposal

- A. Objectives and rationale of the proposed research
- B. Research design, anticipated risks and benefits
 - 1. Structure and characteristics of the biological system
 - 2. Preclinical studies, including risk assessment studies
 - 3. Clinical procedures, including patient monitoring
 - 4. Public health considerations
 - 5. Qualifications of investigators, adequacy of laboratory and clinical facilities
- C. Selection of patients
- D. *Informed consent*
- E. Privacy and confidentiality

II. Special Issues

- A. Provision of accurate information to the public
- B. Timely communication of research methods and results to investigators and clinicians

III. Requested Documentation

- A. Original protocol
- B. IRB and IBC minutes and recommendations
- C. One-page abstract of gene transfer protocol
- D. One-page description of proposed experiment in non-technical language
- E. **Curricula vitae** for professional personnel
- F. Indication of other federal agencies to which the protocol is being submitted
- G. Other pertinent material

IV. Reporting Requirements

National Institutes of Health

**Points to Consider in the Design and Submission of
 Protocols for the Transfer of
 Recombinant DNA into Human Subjects
 Human Somatic Cell Gene Therapy Protocols**

Applicability

These "Points to Consider" apply only to research conducted at or sponsored by an institution that receives any support for recombinant DNA research from the National Institutes of Health (NIH). ~~This includes research performed by NIH directly.~~ Other researchers (e.g., those employed by private companies, institutions, non-United States organizations, and non-profit organizations, etc.) are encouraged to use the "Points to Consider." Experiments in which recombinant DNA is introduced into cells of a human subject with the intent of stably modifying the subject's genome are covered by Section III-A-4 of the NIH Guidelines for Research Involving Recombinant DNA Molecules (49 Federal Register 46266). Section III-A-4 applies both to recombinant DNA and to DNA or RNA derived from recombinant DNA.

Introduction

(1) ~~Experiments in which recombinant DNA (See Footnote 1) is introduced into cells of a human subject with the intent of stably modifying the subject's genome are covered by Section III-A-4 of the NIH Guidelines for Research Involving Recombinant DNA Molecules (49 Federal Register 46266).~~ Section III-A-4 requires such experiments involving the transfer of recombinant DNA into human subjects to be reviewed by the NIH Recombinant DNA Advisory Committee (RAC) and approved by the NIH. RAC consideration of each proposal will be on a case-by-case basis and will follow publication of a precis of the proposal in the Federal Register, an opportunity for public comment, and a review of the proposal by the working group Human Gene Therapy Subcommittee of the RAC. RAC recommendations on each proposal will be forwarded to the NIH Director for a decision which will then be published in the Federal Register. In accordance with Section IV-C-1-b of the NIH Guidelines, the NIH Director may approve proposals only if he finds that they present "no significant risk to health or the environment."

(2) In general, it is expected that somatic cell gene therapy protocols the transfer of recombinant DNA into human subjects will not present a risk to the environment as the recombinant DNA is expected to be confined to the human subject. Nevertheless, Section I-B-4-b of the "Points to Consider" document specifically asks the researchers to address this point.

(3) This document is intended to provide guidance in preparing proposals for NIH consideration under Section III-A-4 of the NIH Guidelines for Research Involving Recombinant DNA Molecules. ~~Not every point mentioned in the "Points to Consider" document will necessarily require attention in every proposal.~~ The document will be considered for revision as experience in evaluating proposals accumulates and as new

scientific developments occur. This review will be carried out ~~at least annually~~ periodically as needed.

(4) A proposal will be considered by the RAC only after the protocol has been approved by the local Institutional Biosafety Committee (IBC) and by the local Institutional Review Board (IRB) in accordance with Department of Health and Human Services (DHHS) Regulations for the Protection of Human Subjects (45 Code of Federal Regulations, Part 46). (If a proposal involves children, special attention should be paid to subpart D of these DHHS regulations.) The IRB and IBC may, at their discretion, condition their approval on further specific deliberation by the RAC and its ~~working group Subcommittee~~. Consideration of ~~gene therapy~~ proposals by the RAC may proceed simultaneously with review by any other involved federal agencies (See Footnote 1) provided that the RAC is notified of the simultaneous review. Meetings of the Committee ~~and the Subcommittee~~ will be open to the public except where trade secrets or proprietary information would be disclosed. The committee ~~would prefer~~ that the first proposals submitted for RAC review contain no proprietary information or trade secrets, enabling all aspects of the review to be open to the public. The public review of these protocols will serve to inform the public not only on the technical aspects of the proposals but also on the meaning and significance of the research.

(5) The clinical application of recombinant DNA techniques ~~to human gene therapy~~ raises two general kinds of questions:

(1) the questions usually discussed by IRBs in their review of any proposed research involving human subjects; and (2) broader ~~social~~ issues. The first type of question is addressed principally in Part I of this document. Several ~~of the broader social issues surrounding human gene therapy~~ are discussed later in this Introduction and in Part II below.

(6) ~~Following the Introduction, this document is divided into four parts. Part I deals with requests a description of the protocol with special attention to the short-term risks and benefits of the proposed research to the patient (See Footnote 2) and to other people, as well as with issues of fairness in the selection of patients, informed consent, and privacy and confidentiality. In Part II, investigators are requested to address special issues pertaining to the free flow of information about the clinical trials of gene therapy. These issues lie outside the usual purview of IRBs and reflect general public concerns about biomedical research. Part III summarizes other requested documentation that will assist the RAC and its working group Subcommittee in their review of gene therapy proposals. Part IV specifies reporting requirements.~~

(7) ~~The RAC and its working group Subcommittee will not at present entertain proposals for germ line alterations but will consider for approval protocols involving somatic cell gene therapy. A distinction should be drawn between making genetic changes in somatic cells and in germ line cells. The purpose of somatic cell gene therapy is to treat an individual patient, e.g., by inserting a properly functioning gene into a patient's bone marrow somatic cells in vitro and then reintroducing the cells~~

into the patient's body. In germ line alterations, a specific attempt is made to introduce genetic changes into the germ (reproductive) cells of an individual, with the aim of changing the set of genes passed on to the individual's offspring.

(8) The acceptability of human somatic cell gene therapy has been addressed in several recent public documents as well as in numerous academic studies. The November 1982 report of the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, **Splicing Life**, resulted from a two-year process of public deliberations and hearings; upon release of that report, a House subcommittee held three days of public hearings with witnesses from a wide range of fields from the biomedical and social sciences to theology, philosophy, and law. In December 1984, the Office of Technology Assessment released a background paper, **Human Gene Therapy**, which brought these earlier documents up to date. As the latter report concluded:

"Civic, religious, scientific, and medical groups have all accepted, in principle, the appropriateness of gene therapy of somatic cells in humans for specific genetic diseases. Somatic cell gene therapy is seen as an extension of present methods of therapy that might be preferable to other technologies."

In light of this public support, the RAC is prepared to consider proposals for somatic cell gene therapy.

(9)

First Revision - Concurring with this judgment, the RAC and its working group Subcommittee are also prepared to consider for approval somatic cell therapy protocols involving the transfer of recombinant DNA into human subjects, provided that

Second Revision - In their evaluation of proposals involving the transfer of recombinant DNA into human subjects, the RAC and its Subcommittee will consider whether

the design of such experiments offers adequate assurance that their consequences will not go beyond their purpose, which is the same as the traditional purpose of all clinical investigations, namely, to benefit the health and well-being of the individual being treated while at the same time gathering generalizable knowledge.

(10) Two possible undesirable consequences of somatic cell therapy the transfer of recombinant DNA would be unintentional: (1) vertical transmission of genetic changes from an individual to his or her offspring or (2) horizontal transmission of viral infection to other persons with whom the individual comes in contact. Accordingly, this document requests information that will enable the RAC and its working group Subcommittee to assess the likelihood that the proposed somatic cell gene therapy experiments will inadvertently affect reproductive cells or lead to infection of other people (e.g., treatment personnel or relatives).

(11) In recognition of the social concern that surrounds the general discussion of ~~human gene therapy recombinant DNA~~, the ~~working group Subcommittee~~ will continue to consider the possible long-range effects of applying knowledge gained from these and related experiments. While research in molecular biology could lead to the development of techniques for germ line intervention or for the use of genetic means to enhance human capabilities rather than to correct defects in patients, the ~~working group Subcommittee~~ does not believe that these effects will follow immediately or inevitably from experiments with somatic cell gene therapy. The ~~working group Subcommittee~~ will cooperate with other groups in assessing the possible long-term consequences of ~~somatic cell gene therapy~~ the transfer of recombinant DNA and related laboratory and animal experiments in order to define appropriate human applications of this emerging technology.

(12) Responses to the questions raised in these "Points to Consider" should be provided in the form of either written answers or references to specific sections of the protocol or its appendices.

(13) ~~Investigators should indicate points which are not applicable with a brief explanation. Investigators submitting proposals that employ essentially the same vector systems (or with minor variations), and/or that are based on the same preclinical testing as proposals previously reviewed by the Human Gene Therapy Subcommittee and the RAC, may refer to preceding documents without having to rewrite such material already reviewed by the Human Gene Therapy Subcommittee and the RAC.~~

I. Description of Proposal

A. Objectives and rationale of the proposed research

State concisely the overall objectives and rationale of the proposed study. Please provide information on the following specific points that relate to whichever type of research is being proposed:

1. Use of recombinant DNA for therapeutic purposes

~~For research in which recombinant DNA is transferred in order to treat a disease or disorder (e.g., genetic diseases, cancer, and metabolic diseases, etc.), the following questions should be addressed:~~

- a. Why is the disease selected for treatment by means of gene therapy a good candidate for such treatment?

- b. Describe the natural history and range of expression of the disease selected for treatment. What objective and/or quantitative measures of disease activity are available? In your view, are the usual effects of the disease predictable enough to allow for meaningful assessment of the results of gene therapy?
- c. Is the protocol designed to prevent all manifestations of the disease, to halt the progression of the disease after symptoms have begun to appear, or to reverse manifestations of the disease in seriously ill victims?
- d. What alternative therapies exist? In what groups of patients are these therapies effective? What are their relative advantages and disadvantages as compared with the proposed gene therapy?

2. Transfer of DNA for Other Purposes

- a. Into what cells will the recombinant DNA be transferred? Why is the transfer of recombinant DNA necessary for the proposed research? What questions can be answered by using recombinant DNA?
- b. What alternative methodologies exist? What are their relative advantages and disadvantages as compared to the use of recombinant DNA?

B. Research design, anticipated risks and benefits

1. Structure and characteristics of the biological system

Provide a full description of the methods and reagents to be employed for gene delivery and the rationale for their use. The following are specific points to be addressed:

- a. What is the structure of the cloned DNA that will be used?
 - (1) Describe the gene (genomic or cDNA), the bacterial plasmid or phage vector, and the delivery vector (if any). Provide complete nucleotide sequence analysis or a detailed restriction enzyme map of the total construct.
 - (2) What regulatory elements does the construct contain (e.g., promoters, enhancers, polyadenylation sites, replication origins, etc.)?

- (3) Describe the steps used to derive the DNA construct.
- b. What is the structure of the material that will be administered to the patient?
- (1) Describe the preparation, structure, and composition of the materials that will be given to the patient or used to treat the patient's cells.
- (a) If DNA, what is the purity (both in terms of being a single DNA species and in terms of other contaminants)? What tests have been used and what is the sensitivity of the tests?
- (b) If a virus, how is it prepared from the DNA construct? In what cell is the virus grown (any special features)? What medium and serum are used? How is the virus purified? What is its structure and purity? What steps are being taken (and assays used with their sensitivity) to detect and eliminate any contaminating materials (for example, VL30 RNA, other nucleic acids, or proteins) or contaminating viruses or other organisms in the cells or serum used for preparation of the virus stock?
- (c) If co-cultivation is employed, what kinds of cells are being used for co-cultivation? What steps are being taken (and assays used with their sensitivity) to detect and eliminate any contaminating materials? Specifically, what tests are being done to assess the material to be returned to the patient for the presence of live or killed donor cells or other non-vector materials (for example, VL30 sequences) originating from those cells?
- (d) If methods other than those covered by (a)-(c) are used to introduce new genetic information into target cells, what steps are being taken to detect and eliminate any contaminating materials? What are possible sources of contamination? What is the sensitivity of tests used to monitor contamination?
- (2) Describe any other material to be used in preparation of the material to be administered to the patient. For example, if a viral vector is proposed, what is the nature of the helper virus or cell line? If carrier particles are

to be used, what is the nature of these?

2. Preclinical studies, including risk-assessment studies

Describe ~~and justify~~ the experimental basis (derived from tests in cultured cells and animals) for claims about the efficacy and safety of the proposed system for gene delivery and explain why the model(s) chosen is (are) the most appropriate.

a. Laboratory studies of the delivery system

- (1) What cells are the intended recipients of gene therapy recombinant DNA? If recipient cells are to be treated *in vitro* and returned to the patient, how will the cells be characterized before and after treatment? What is the theoretical and practical basis for assuming that only the treated cells will act as recipients?
- (2) Is the delivery system efficient? What percentage of the target cells contain the added DNA?
- (3) How is the structure of the added DNA sequences monitored and what is the sensitivity of the analysis? Is the added DNA extrachromosomal or integrated? Is the added DNA unrearranged?
- (4) How many copies are present per cell? How stable is the added DNA both in terms of its continued presence and its structural stability?

b. Laboratory studies of gene expression

Is the added gene expressed? To what extent is expression only from the desired gene (and not from the surrounding DNA)? To what extent does the insertion modify the expression of other genes? In what percentage of cells does expression from the added DNA occur? Is the product biologically active? What percentage of normal activity results from the inserted gene? Is the gene expressed in cells other than the target cells? If so, to what extent?

c. Laboratory studies pertaining to the safety of the delivery/expression system

- (1) If a retroviral system is used:
 - (a) What cell types have been infected with the

retroviral vector preparation? Which cells, if any, produce infectious particles?

- (b) How stable are the retroviral vector and the resulting provirus against loss, rearrangement, recombination, or mutation? What information is available on how much rearrangement or recombination with endogenous or other viral sequences is likely to occur in the patient's cells? What steps have been taken in designing the vector to minimize instability or variation? What laboratory studies have been performed to check for stability, and what is the sensitivity of the analyses?
 - (c) What laboratory evidence is available concerning potential harmful effects of the treatment transfer, e.g., development of neoplasia, harmful mutations, regeneration of infectious particles, or immune responses? What steps have been taken in designing the vector to minimize pathogenicity? What laboratory studies have been performed to check for pathogenicity, and what is the sensitivity of the analyses?
 - (d) Is there evidence from animal studies that vector DNA has entered untreated cells, particularly germ line cells? What is the sensitivity of the analyses?
 - (e) Has a protocol similar to the one proposed for a clinical trial been carried out in non-human primates and/or other animals? What were the results? Specifically, is there any evidence that the retroviral vector has recombined with any endogenous or other viral sequences in the animals?
- (2) If a non-retroviral delivery system is used: What animal studies have been done to determine if there are pathological or other undesirable consequences of the protocol (including insertion of DNA into cells other than those treated, particularly germ line cells)? How long have the animals been studied after treatment? What tests have been used and what is their sensitivity?

3. Clinical procedures, including patient monitoring

Describe the treatment that will be administered to patients and the diagnostic methods that will be used to monitor the success or failure of the treatment. If previous clinical studies using similar methods have been performed by yourself or

others, indicate their relevance to the proposed study.

- a. Will cells (e.g., bone marrow cells) be removed from patients and treated ~~in vitro in preparation for gene therapy~~? If so, what kinds of cells will be removed from the patients, how many, how often, and at what intervals?
- b. Will patients be treated to eliminate or reduce the number of cells containing malfunctioning genes (e.g., through radiation or chemotherapy) ~~prior to gene therapy~~?
- c. What treated cells (or vector/DNA combination) will be given to patients ~~in the attempt to administer gene therapy~~? How will the treated cells be administered? What volume of cells will be used? Will there be single or multiple treatments? If so, over what period of time?
- d. What are the clinical endpoints of the study? Are there objective and quantitative measurements to assess the natural history of the disease? Will such measurements be used in following ~~your~~ patients? How will patients be monitored to assess specific effects of the treatment on the disease? What is the sensitivity of the analyses? How frequently will follow-up studies be done? How long will patient follow-up continue?
- e. What are the major ~~potential~~ beneficial and adverse effects of treatment that you anticipate? What measures will be taken in an attempt to control or reverse these adverse effects if they occur? Compare the probability and magnitude of potential adverse effects on patients with the probability and magnitude of deleterious consequences from the disease if ~~gene therapy~~ ~~recombinant DNA~~ is not performed.
- f. If a treated patient dies, what special ~~post mortem~~ studies will be performed ~~as part of the autopsy~~?

4. Public health considerations

Describe any potential benefits and hazards of the proposed therapy to persons other than the patients being treated. Specifically:

- a. On what basis are potential public health benefits or hazards postulated?
 - b. Is there a significant ~~likelihood~~ possibility that the added DNA will spread from the patient to other persons or to the environment?
 - c. What precautions will be taken against such spread (e.g., to patients sharing a room, health-care workers, or family members)?
 - d. What measures will be undertaken to mitigate the risks, if any, to public health?
5. Qualifications of investigators, adequacy of laboratory and clinical facilities

Indicate the relevant training and experience of the personnel who will be involved in the preclinical studies and clinical administration of gene-therapy recombinant DNA. In addition, please describe the laboratory and clinical facilities where the proposed study will be performed.

- a. What professional personnel (medical and nonmedical) will be involved in the proposed study? What are their specific qualifications and experience with respect to the disease to be treated ~~and with respect to~~ the techniques employed in molecular biology? Please provide curricula vitae (see Section III-E).
 - b. At what hospital or clinic will the treatment be given? Which facilities of the hospital or clinic will be especially important for the proposed study? Will patients occupy regular hospital beds or clinical research center beds? Where will patients reside during the follow-up period? What special arrangements will be made for the comfort and consideration of the patients?
- C. Selection of patients

Estimate the number of patients to be involved in the proposed study ~~of gene-therapy~~. Describe recruitment procedures and patient eligibility requirements, paying particular attention to whether these procedures and requirements are fair and equitable.

1. How many patients do you plan to involve in the proposed study?

164

2. How many eligible patients do you anticipate being able to identify each year?
3. What recruitment procedures do you plan to use?
4. What selection criteria do you plan to employ? What are the exclusion and inclusion criteria for the study?
5. How will patients be selected if it is not possible to include all who desire to participate?

D. Informed consent

Indicate how patients will be informed about the proposed study and how their consent will be solicited. The consent procedure should adhere to the requirements of DHHS regulations for the protection of human subjects (45 Code of Federal Regulations, Part 46). If the study involves pediatric or mentally handicapped patients, describe procedures for seeking the permission of parents or guardians and, where applicable, the assent of each patient. Areas of special concern highlighted below include potential adverse effects, financial costs, privacy, ~~and~~ long-term follow-up, and post mortem examination.

1. How will the major points covered in Sections I-A through I-C of this document be disclosed to potential participants in this study and/or parents or guardians in language that is understandable to them?
2. How will the innovative character and the theoretically possible adverse effects of ~~gene therapy~~ the experiment be discussed with patients and/or parents or guardians? How will the potential adverse effects be compared with the consequences of the disease? What will be said to convey that some of these adverse effects, if they occur, could be irreversible?
3. What explanation of the financial costs of ~~gene therapy~~ the experiment and any available alternatives ~~therapies~~ will be provided to patients and/or parents or guardians?
4. How will patients and/or their parents or guardians be informed that the innovative character of ~~gene therapy~~ the experiment may lead to great interest by the media in the research and in treated patients?
5. How will patients and/or their parents or guardians be informed:

- a. ~~About the irreversible consequences of some of the~~ That some of the procedures performed in the study may be irreversible?
- b. ~~That following the performance of such procedures it would not be medically advisable for patients to withdraw from the study?~~
~~That there may be~~ About any adverse medical consequences that may occur if a subject of withdraws from the study once it has begun?
- c. ~~That~~ About a willingness to cooperate in long-term follow-up (for at least three to five years) will be a precondition for participation in the study expected?
- d. ~~That a~~ About whether willingness to permit an autopsy to be performed in the event of a patient's death following ~~treatment~~ transfer is also a precondition for a patient's participation in the study? (This stipulation is included because an accurate determination of the precise cause of a patient's death would be of vital importance to all future gene therapy patients.)

E. Privacy and confidentiality

Indicate what measures will be taken to protect the privacy of gene therapy patients and their families as well as to maintain the confidentiality of research data.

1. What provisions will be made to honor the wishes of individual patients (and the parents or guardians of pediatric or mentally handicapped patients) as to whether, when, or how the identity of patients is publicly disclosed?
2. What provision will be made to maintain the confidentiality of research data, at least in cases where data could be linked to individual patients?

II. Special Issues

Although the following issues are beyond the normal purview of local IRBs, the RAC and its ~~working group~~ Subcommittee request that investigators respond to questions A and B below.

- A. What steps will be taken, consistent with point I-E above, to ensure that accurate information is made available to the public with respect to such public concerns as may arise from the proposed study?
- B. Do you or your funding sources intend to protect under patent or trade secret laws either the products or the procedures developed in the proposed study? If so, what steps will be taken to permit as full communication as possible among investigators and clinicians concerning research methods and results?

III. Requested Documentation

In addition to responses to the questions raised in these "Points to Consider," please submit the following materials:

- A. Your protocol as approved by your local IRB and IBC. ~~The consent form, which must have IRB approval, should be submitted to the NIH only on request.~~
- B. Results of local IRB and IBC minutes deliberations and recommendations that pertain to your protocol.
- C. A one-page scientific abstract of the ~~gene therapy~~ protocol.
- D. A one-page description of the proposed experiment in nontechnical language.
- E. Curricula vitae for professional personnel.
- F. An indication of other federal agencies to which the protocol is being submitted for review.
- G. Any other material which you believe will aid in the review.

IV. Reporting Requirements

- A. Serious adverse effects of treatment should be reported immediately to both ~~your~~ the local IRB and the NIH Office for Protection from Research Risks, and a written report should be filed with both groups. A copy of the report should also be forwarded to the NIH Office of Recombinant DNA Activities (ORDA).
- B. Reports regarding the general progress of patients should be filed ~~at six-month intervals~~ with both your local IRB and ORDA within 6 months of the commencement of the experiment and at six-month intervals thereafter. These twice-yearly reports should continue for a sufficient period of time to allow observation of all major effects ~~(at~~

least three to five years). In the event of a patient's death, the autopsy report, a summary of the special post mortem studies and statement of the cause of death should be submitted to the IRB and ORDA, if available.

Footnotes:

1. The Food and Drug Administration (FDA) has jurisdiction over drug products intended for use in clinical trials of human somatic-cell gene therapy. For general information on FDA's policies and regulatory requirements, please see the **Federal Register**, Volume 51, pages 23309-23313, 1986.
2. The term "patient" and its variants are used in the text as a shorthand designation for "patient-subject."